Altay Therapeutics
Altay Therapeutics (Altay) is developing small molecule therapies to treat chronic inflammation and cancers by targeting disease-causing transcription factors. Preliminary data of the lead candidate, PCE1911, has been shown to treat Ewing’s Sarcoma. Further, mouse data on the second candidate, E46, has been shown to prevent and reverse lung fibrosis.